Not yet recruitingNot applicableNCT07384936

Topefilgrastim Injection in the Treatment of High-Risk Pregnant Patients With Preeclampsia

Studying Preeclampsia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fang Wang
Principal Investigator
Fang Wang
Lanzhou University Second Hospital
Intervention
Topefilgrastim Injection(drug)
Enrollment
100 target
Eligibility
18-45 years · FEMALE
Timeline
20262027

Study locations (1)

Collaborators

Xiamen Amoytop Biotech Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07384936 on ClinicalTrials.gov

Other trials for Preeclampsia

Additional recruiting or active studies for the same condition.

See all trials for Preeclampsia

← Back to all trials